News headlines about Collegium Pharmaceutical (NASDAQ:COLL) have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Collegium Pharmaceutical earned a news impact score of 0.24 on Accern’s scale. Accern also gave news stories about the specialty pharmaceutical company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern’s rankings:
- Tale of the Ticker: Collegium Pharmaceutical Inc (COLL) Moves on Volume – Evergreen Caller (evergreencaller.com)
- Collegium Pharmaceutical, Inc. (COLL) Expected to Announce Quarterly Sales of $4.33 Million (americanbankingnews.com)
- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Trading Down – Short Interest Up 11.33% – Highlight Press (highlightpress.com)
- Unusual Activity Spotted in Collegium Pharmaceutical Inc (COLL) – Evergreen Caller (evergreencaller.com)
- Upper Respiratory Tract Treatment Infection Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2016–2024 (sbwire.com)
Several equities research analysts recently commented on COLL shares. Janney Montgomery Scott reaffirmed a “buy” rating and set a $25.00 target price on shares of Collegium Pharmaceutical in a research note on Monday, June 12th. Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, June 9th. Jefferies Group LLC reaffirmed a “buy” rating and set a $22.00 target price (down previously from $24.00) on shares of Collegium Pharmaceutical in a research note on Thursday, May 11th. Finally, Zacks Investment Research cut Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Tuesday, March 14th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Collegium Pharmaceutical currently has an average rating of “Buy” and a consensus target price of $22.83.
Shares of Collegium Pharmaceutical (COLL) traded up 5.68% on Wednesday, reaching $11.91. The company’s stock had a trading volume of 466,498 shares. The company’s 50 day moving average price is $9.32 and its 200 day moving average price is $12.90. Collegium Pharmaceutical has a 12-month low of $7.37 and a 12-month high of $20.55. The company’s market cap is $350.84 million.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.19. The firm had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $3.55 million. Analysts forecast that Collegium Pharmaceutical will post ($3.07) EPS for the current fiscal year.
In other news, insider Paul Brannelly bought 10,000 shares of Collegium Pharmaceutical stock in a transaction on Friday, May 12th. The shares were purchased at an average price of $9.18 per share, for a total transaction of $91,800.00. Following the acquisition, the insider now owns 110,227 shares of the company’s stock, valued at $1,011,883.86. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 25.76% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by sleekmoney and is the property of of sleekmoney. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://sleekmoney.com/collegium-pharmaceutical-coll-receives-coverage-optimism-rating-of-0-24/1929122.html.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/collegium-pharmaceutical-coll-receives-coverage-optimism-rating-of-0-24/1929122.html
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.